Physician profile
Shareen Sutherland
NPI 1285275206
$775.15
in general payments reported to CMS, 2019-2025
20 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $96.71 · 2024: $227 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.29 | 2023-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $67.47 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.07 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $42.13 | 2025 | Ozempic, Wegovy |
| Abbvie INC. | $40.91 | 2025 | |
| Glaxosmithkline, LLC. | $39.67 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $39.44 | 2024-2025 | |
| Amgen INC. | $36.73 | 2024 | Prolia, Evenity, Repatha |
| Exact Sciences Corporation | $33.71 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $29.78 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.04 | 2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $28.46 | 2023-2024 | Mounjaro |
| Dexcom, INC. | $24.68 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $24.44 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $23.39 | 2025 | Capvaxive |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.27 | 2025 | |
| Lucid Diagnostics INC. | $19.67 | 2024 | |
| Lundbeck LLC | $17.36 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $17.35 | 2025 | Gemtesa |
| Organogenesis INC. | $13.29 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shareen Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.